NYSE:FRX - Forest Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Receive FRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
CUSIP34583810
Phone+1-212-4217850

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Forest Laboratories (NYSE:FRX) Frequently Asked Questions

What is Forest Laboratories' stock symbol?

Forest Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "FRX."

Has Forest Laboratories been receiving favorable news coverage?

News articles about FRX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Forest Laboratories earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the healthcare company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.

What other stocks do shareholders of Forest Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forest Laboratories investors own include Celgene (CELG), Gilead Sciences (GILD), Starbucks (SBUX), Boeing (BA), Bank of America (BAC), salesforce.com (CRM), Michael Kors (KORS), Las Vegas Sands (LVS), Schlumberger (SLB) and Constellation Brands (STZ).

How do I buy shares of Forest Laboratories?

Shares of FRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Forest Laboratories' official website?

The official website for Forest Laboratories is http://www.frx.com.

How can I contact Forest Laboratories?

Forest Laboratories' mailing address is 909 3rd Ave, NEW YORK, NY 10022-4731, United States. The healthcare company can be reached via phone at +1-212-4217850.


MarketBeat Community Rating for Forest Laboratories (NYSE FRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  533
MarketBeat's community ratings are surveys of what our community members think about Forest Laboratories and other stocks. Vote "Outperform" if you believe FRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel